<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00271271</url>
  </required_header>
  <id_info>
    <org_study_id>L_8907</org_study_id>
    <nct_id>NCT00271271</nct_id>
  </id_info>
  <brief_title>Efficacy Study of GEMOX Combination and Vinorelbine in NSCL Patients</brief_title>
  <acronym>GON</acronym>
  <official_title>Phase II Clinical Trial With the Combination Gemcitabine, Oxaliplatin and Vinorelbine as First Line Treatment in Patients With Non-small Cell Bronchopulmonary Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary:&#xD;
&#xD;
      ·To evaluate the activity of the combination of gemcitabine, oxaliplatin and vinorelbine as&#xD;
      first line treatment in patients with non-small cell bronchopulmonary cancer&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      ·To evaluate the toxicity of the combination&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">October 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective rate of response (ORR) according to the RECIST criterion, as evaluated by a review panel of outside experts.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS), Overall survival (OS)</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatine / gemcitabine / Vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-small cell bronchopulmonary cancer established by histological and/or cytological&#xD;
             methods;&#xD;
&#xD;
          -  Advanced or metastatic disease (stage IIIB or IV);&#xD;
&#xD;
          -  At least one measurable lesion with one dimension (&gt;= 20 mm by CT scan or &gt;=10 mm by&#xD;
             CT scan) outside of the irradiated area;&#xD;
&#xD;
          -  No prior chemotherapy;&#xD;
&#xD;
          -  Previous radiotherapy permitted as long as there has been a washout period of at least&#xD;
             4 weeks;&#xD;
&#xD;
          -  Age &gt;= 18 years old;&#xD;
&#xD;
          -  ECOG Performance Status (PS): 0-1;&#xD;
&#xD;
          -  Life expectancy &gt;3 months;&#xD;
&#xD;
          -  Hepatic and renal functions and blood count satisfactory:&#xD;
&#xD;
               -  Blood counts: white blood cells &gt;= 3.0 x 10^9/l, neutrophils &gt;= 1.5 x 10^9/l,&#xD;
                  platelets &gt;= 150 x 10^9/l, haemoglobin &gt;= 9 g/dl,&#xD;
&#xD;
               -  Hepatic function: bilirubin within the limit of the normal upper value, aspartate&#xD;
                  transaminases (AST) or alanine transaminases (ALT) &lt;= 2.5 times the normal upper&#xD;
                  value&#xD;
&#xD;
               -  Renal function: creatinine clearance (calculated according to Cockroft and Gault)&#xD;
                  &gt;= 40 ml/min;&#xD;
&#xD;
          -  Patients of reproductive age must use an effective contraceptive method;&#xD;
&#xD;
          -  Informed consent form signed before any procedure undertaken connected with the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding patient;&#xD;
&#xD;
          -  Past record of other cancers (excluding basocellular or epidermoid cutaneous carcinoma&#xD;
             or cured carcinoma of the cervix);&#xD;
&#xD;
          -  Symptomatic cerebral or leptomeningeal metastases;&#xD;
&#xD;
          -  Symptomatic peripheral neuropathy &gt; 1 (NCI-CTC grade);&#xD;
&#xD;
          -  Presence of a serious disease or medical condition incompatible with the study (at the&#xD;
             discretion of the investigator);&#xD;
&#xD;
          -  Treatment with another test product or participation in another therapeutic trial in&#xD;
             the 4 weeks preceding inclusion in the study;&#xD;
&#xD;
          -  Concomitant treatment by any other anticancer therapy;&#xD;
&#xD;
          -  Concomitant treatment with phenytoin.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie SEBILLE, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 29, 2005</study_first_submitted>
  <study_first_submitted_qc>December 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2005</study_first_posted>
  <last_update_submitted>December 4, 2009</last_update_submitted>
  <last_update_submitted_qc>December 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

